



Monday / June 1, 2020

09:00 - 12:00	Urogenital		<p>Presented by: Prof. Dr. med. Jörg Beyer, Prof. Dr. med. Silke Gillessen, PD Dr. Thomas Herrmanns</p> <p>Live expert: PD Dr. med. Ali Afshar-Oromieh, Dr. Stefanie Hayoz, Prof. Dr. med. Wolfram Jochum, PD Dr. med. Ulf Petrusch, Prof. Dr. med. Daniel R. Zwahlen</p>	
Abstract no	Entity	First Author	Titel	Link to the video
5504	Prostate	Efstathiou	Neoadjuvant apalutamide (APA) plus leuprolide (LHRHa) with or without abiraterone (AA) in localized high-risk prostate cancer (LHRPC).	https://meetinglibrary.asco.org/record/187134/video
5001	Prostate	Shore	HERO phase III trial: Results comparing relugolix, an oral GnRH receptor antagonist, versus leuprolide acetate for advanced prostate cancer	https://meetinglibrary.asco.org/record/191602/video
Discussion			End of traditional approaches? Neoadjuvant treatment and replacement of subcutaneous ADT by oral antagonists	
5500	Prostate	Hofman	TheraP: A randomised phase II trial of 177Lu-PSMA-617 (LuPSMA) theranostic versus cabazitaxel in metastatic castration resistant prostate cancer (mCRPC) progressing after docetaxel: Initial results (ANZUP protocol 1603).	https://meetinglibrary.asco.org/record/187000/video
Discussion			PSMA in diagnosis and treatment: which one and when?	
5513	Prostate	Eldred-Evans	Population-based prostate cancer screening using a prospective, blinded, paired screen-positive comparison of PSA and fast MRI: The IP1-PROSTAGRAM study	https://meetinglibrary.asco.org/record/187454/video
Discussion			Better prostate cancer screening by using MRI?	
5000	Bladder	Hussain	IMvigor010: Primary analysis from a phase III randomized study of adjuvant atezolizumab (atezo) versus observation (obs) in high-risk muscle-invasive urothelial carcinoma (MIUC).	https://meetinglibrary.asco.org/record/185947/video
LBA 1	Bladder	Powles	Maintenance avelumab + best supportive care (BSC) versus BSC alone after platinum-based first-line (1L) chemotherapy in advanced urothelial carcinoma (UC): JAVELIN Bladder 100 phase III interim analysis.	https://meetinglibrary.asco.org/record/186872/video
Discussion			Immunotherapy in bladder cancer: which agent when?	
5001	Renal	Plimack	Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced renal cell carcinoma (RCC): Updated analysis of KEYNOTE-426.	https://meetinglibrary.asco.org/record/185941/video
No Abstract	Renal	Heng	New and Updated Pivotal Trials of Single Agent and Combination Immunocheckpoint Blockers in Bladder and Kidney Cancers	https://meetinglibrary.asco.org/record/191129/video
Discussion			Controversy – do really all patients need immunotherapy upfront?	
5006	Renal	Atkins	Phase II study of nivolumab and salvage nivolumab + ipilimumab in treatment-naïve patients (pts) with advanced renal cell carcinoma (RCC) (HCRN GU16-260).	https://meetinglibrary.asco.org/record/185946/video
5008	Renal	Lee	Phase II trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) for disease progression after PD-1/PD-L1 immune checkpoint inhibitor (ICI) in metastatic clear cell renal cell carcinoma (mccRCC).	https://meetinglibrary.asco.org/record/186053/video
Discussion			Taking into consideration not only about first-line but also about second-line options	

Organizer



Founding Sponsor



Roche Pharma (Schweiz) AG
4052 Basel

Co-Sponsors

